- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03127215
Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors (NCT-PMO-1603)
August 28, 2023 updated by: National Center for Tumor Diseases, Heidelberg
A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Evaluation of the efficacy of the combination of olaparib and trabectedin in adult patients with locally advanced/metastatic solid tumors that failed standard treatment and whose molecular sequencing tumor profiles show homologous recombination repair (HRR) defects.
The primary objective is to show superior disease control rate in patients with HRR-deficient tumors treated with olaparib and trabectedin compared to treatment according to current guidelines (physician's choice).
This trial aims to establish whether the PARP-dependency of HRR-deficient tumors across entities can be exploited for therapeutic benefit.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
102
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Richard Schlenk, MD
- Phone Number: 6228 +49622156
- Email: studienzentrale@nct-heidelberg.de
Study Locations
-
-
-
Dresden, Germany, 01307
- Medizinische Fakultät der TU Dresden
-
Essen, Germany, 45147
- Universitatsklinikum Essen
-
Frankfurt, Germany, 60590
- Universitatsklinikum Frankfurt
-
Freiburg, Germany, 79106
- Universitätsklinikum Freiburg
-
Heidelberg, Germany, 69120
- National Center for Tumordiseases (NCT)
-
Mainz, Germany, 55131
- Universitätsmedizin der Johannes-Gutenberg-Universität Mainz
-
München, Germany, 81377
- Klinikum der Universität München-Großhadern
-
Stuttgart, Germany, 70376
- Klinik Schillerhohe
-
Tuebingen, Germany, 72076
- Universitatsklinikum Tubingen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Main Inclusion Criteria:
- Written informed consent
- Progressive locally advanced or metastatic malignancy
- Prior administration of standard treatment for primary and relapsed malignancy
- Eastern Cooperative Oncology Group Performance Status ≤1
- Patients with central venous access device in place (central venous catheter or porta-cath)
- Age ≥18 and ≤70 years
- Identification of defective DNA repair via HR
- Adequate bone marrow, renal, and hepatic function
- Hemoglobin ≥10 g/dl
- Neutrophil count ≥1,500/mm3
- Platelet count ≥100,000/µl
- Bilirubin ≤1.5 x upper limit of normal (ULN)
- ALT and AST ≤2.5 x ULN (≤5 x ULN in patients with hepatic tumor involvement)
- Alkaline phosphatase ≤2.5 x ULN
- PT-INR/PTT ≤1.5 x ULN
- Albumin ≥25 g/l
- Creatine kinase ≤2.5 x ULN
- Serum creatinine 1.5 mg/dl or creatinine clearance 51 ml/min
Main Exclusion Criteria:
- Hematological malignancies and primary brain tumors.
- Concurrent treatment in another interventional clinical trial
- Prior treatment with PARP Inhibitors
- Patients with platinum-refractory disease, defined as progressive disease during or immediately after treatment with platinum based chemotherapy
- Persistent toxicity (> Grade 2 according to CTCAE 5.0)
- Dementia or significant impairment of cognitive state
- History of HIV infection
- Clinical signs of active infection (>Grade 2 according to CTCAE 4.03)
- History of viral hepatitis (HBV or HCV)
- Epilepsy requiring pharmacologic treatment
- Pregnancy
- Major surgical intervention 4 weeks prior to study inclusion
- Known hypersensitivity to any of the study drugs
- Hematologic malignancy
- QTc time prolongation >500 ms or history of familial long-QT-syndrome
- Heart failure NYHA III/IV
- Severe obstructive or restrictive ventilation disorder
- Concomitant use of known strong CYP3A Inhibitors
- Concomitant use of known strong CYP3A inducers
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm E: Olaparib / Trabectedin
Olaparib / Trabectedin
|
Olaparib 150 mg tablet
Trabectedin 1.1mg/m² infusional solution
|
Other: Arm C: Physician's choice
Physician's choice
|
treatment according to current guidelines
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate
Time Frame: At week 16 (after 5 cycles of study medication)
|
Randomized, open-label, multicenter phase-II study comparing olaparib in combination with trabectedin versus physician's choice.
Primary efficacy endpoint is the disease control rate after 5 cycles.
|
At week 16 (after 5 cycles of study medication)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Time from first administration of the IMP to time death from any cause until end of study (2.5 years)
|
defined as the time from first administration of the IMP to time of death from any cause
|
Time from first administration of the IMP to time death from any cause until end of study (2.5 years)
|
Incidence of Treatment-Emergent Adverse Events
Time Frame: Time from first administration of the IMP to subjects end of trial (approximately month 6)
|
This endpoint includes all AEs, their severity, SAEs, the relation of AEs to the study treatment, dose modifications for toxicity and discontinuation of study treatment during the trial phase.
Toxic effects will be graded according to the National Cancer Institute Common Toxicity Criteria.
|
Time from first administration of the IMP to subjects end of trial (approximately month 6)
|
Patient reported outcomes
Time Frame: Before the first (week 0), at the third (week 8), and after the fifth treatment cycle (week 16)
|
Patient reported outcomes (PROs) including health-related quality of life (QoL) are calculated as the new European Organization for Research and Treatment of Cancer (EORTC).
QLQ-C30 summary score recommended by teh EORTC Quality of Life Group.
In addition, the EORTC QLQ function and symptom scores are calculated according to the actual EORTC Scoring Manual.
|
Before the first (week 0), at the third (week 8), and after the fifth treatment cycle (week 16)
|
Tumor response rate
Time Frame: At week 16 (after 5 cycles of study medication)
|
Defined as the sum of complete remission (CR) and partial remission (PR) according to RECIST version 1.1 after 5 cycles of study medication
|
At week 16 (after 5 cycles of study medication)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Stefan Froehling, MD, NCT / DKFZ Heidelberg
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 25, 2018
Primary Completion (Estimated)
December 1, 2023
Study Completion (Estimated)
December 1, 2023
Study Registration Dates
First Submitted
March 31, 2017
First Submitted That Met QC Criteria
April 24, 2017
First Posted (Actual)
April 25, 2017
Study Record Updates
Last Update Posted (Actual)
August 29, 2023
Last Update Submitted That Met QC Criteria
August 28, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCT-2017-0417
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancers With DNA Repair-Deficiency
-
University of British ColumbiaUnknownOxidative Stress | Sleep Quality | DNA Damage Repair Deficiency
-
Deciphera Pharmaceuticals LLCTerminatedMetastatic Solid Tumors | Locally Advanced Tumors | Cancers With MET Genomic Alterations | Cancers With TRK Genomic AlterationsUnited States
-
Hoffmann-La RocheNo longer availableCancers With RET AlterationsUnited States
-
Federal Research Institute of Pediatric Hematology...RecruitingNijmegen Breakage SyndromeRussian Federation
-
Federal Research Institute of Pediatric Hematology...RecruitingNijmegen Breakage SyndromeRussian Federation
-
Harpoon TherapeuticsCompletedAdvanced Cancers Associated With Mesothelin ExpressionUnited States
-
Hoffmann-La RocheNo longer availableCancers With NTRK, ROS1, or ALK Gene FusionsUnited States
-
Asan Medical CenterRecruitingBiliary Tract Cancer | DNA Damage Repair DeficiencyKorea, Republic of
-
Seattle Institute for Biomedical and Clinical ResearchVA Puget Sound Health Care System; Prostate Cancer FoundationTerminatedMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States
-
Clinuvel (UK) Ltd.CompletedAfamelanotide Evaluated as Skin DNA Repair Therapy in Healthy VolunteersUnited Kingdom
Clinical Trials on Olaparib
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingSmall Cell Lung Carcinoma | Small-cell Lung CancerUnited States
-
AstraZenecaMerck Sharp & Dohme LLC; Iqvia Pty LtdCompletedMalignant Solid TumorBelgium
-
CSPC Ouyi Pharmaceutical Co., Ltd.CompletedHealthy ParticipantsChina
-
Dana-Farber Cancer InstituteNovartis; AstraZenecaCompleted
-
AstraZenecaEuropean Network of Gynaecological Oncological Trial Groups (ENGOT)CompletedEpithelial Ovarian CancerDenmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
-
Nordic Society of Gynaecological Oncology - Clinical...Hellenic Cooperative Oncology Group; European Network of Gynaecological Oncological... and other collaboratorsRecruiting
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaboratorsActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA MutatedKorea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
-
SandozCompleted
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Leiden University Medical CenterUniversity Medical Center Groningen; Erasmus Medical CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Ovarian Neoplasm EpithelialNetherlands